![Hugues Bienaymé](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hugues Bienaymé
Director Ejecutivo en ORPHELIA Pharma SAS .
Cargos activos de Hugues Bienaymé
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | Director/Miembro de la Junta | 01/01/2007 | - |
Director Ejecutivo | 01/01/2007 | - | |
Director Técnico/Científico/I+D | 01/01/2007 | - | |
Fundador | 01/01/2007 | - |
Historial de carrera de Hugues Bienaymé
Antiguos cargos conocidos de Hugues Bienaymé.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Director Técnico/Científico/I+D | 20/03/1998 | - |
Fundador | 22/12/2009 | 17/10/2012 | |
Corporate Officer/Principal | 22/12/2009 | 17/10/2012 | |
Rhône-Poulenc, Inc. | Corporate Officer/Principal | - | - |
Chrysalon SA
![]() Chrysalon SA Miscellaneous Commercial ServicesCommercial Services Chrysalon SA is a French company that researches and develops medicinal chemical products and pharmaceuticals. The company is based in Villeurbanne, France. Chrysalon was acquired by Urogene SA on March 31, 2002. | Corporate Officer/Principal | 01/01/2001 | 01/01/2003 |
Estadísticas
Internacional
Francia | 4 |
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Founder | 2 |
Sectorial
Commercial Services | 3 |
Process Industries | 2 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
Chrysalon SA
![]() Chrysalon SA Miscellaneous Commercial ServicesCommercial Services Chrysalon SA is a French company that researches and develops medicinal chemical products and pharmaceuticals. The company is based in Villeurbanne, France. Chrysalon was acquired by Urogene SA on March 31, 2002. | Commercial Services |
Rhône-Poulenc, Inc. | Process Industries |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | Health Technology |
- Bolsa de valores
- Insiders
- Hugues Bienaymé
- Experiencia